• Je něco špatně v tomto záznamu ?

The Effect of Hypoxia and Metformin on Fatty Acid Uptake, Storage, and Oxidation in L6 Differentiated Myotubes

M. Musutova, M. Elkalaf, N. Klubickova, M. Koc, S. Povysil, J. Rambousek, B. Volckaert, F. Duska, MD. Trinh, M. Kalous, J. Trnka, K. Balusikova, J. Kovar, J. Polak,

. 2018 ; 9 (-) : 616. [pub] 20181017

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001590

Grantová podpora
NV15-30155A MZ0 CEP - Centrální evidence projektů

Metabolic impairments associated with obstructive sleep apnea syndrome (OSA) are linked to tissue hypoxia, however, the explanatory molecular and endocrine mechanisms remain unknown. Using gas-permeable cultureware, we studied the chronic effects of mild and severe hypoxia on free fatty acid (FFA) uptake, storage, and oxidation in L6 myotubes under 20, 4, or 1% O2. Additionally, the impact of metformin and the peroxisome proliferator-activated receptor (PPAR) β/δ agonist, called GW501516, were investigated. Exposure to mild and severe hypoxia reduced FFA uptake by 37 and 32%, respectively, while metformin treatment increased FFA uptake by 39% under mild hypoxia. GW501516 reduced FFA uptake under all conditions. Protein expressions of CD36 (cluster of differentiation 36) and SCL27A4 (solute carrier family 27 fatty acid transporter, member 4) were reduced by 17 and 23% under severe hypoxia. Gene expression of UCP2 (uncoupling protein 2) was reduced by severe hypoxia by 81%. Metformin increased CD36 protein levels by 28% under control conditions and SCL27A4 levels by 56% under mild hypoxia. Intracellular lipids were reduced by mild hypoxia by 18%, while in controls only, metformin administration further reduced intracellular lipids (20% O2) by 36%. Finally, palmitate oxidation was reduced by severe hypoxia, while metformin treatment reduced non-mitochondrial O2 consumption, palmitate oxidation, and proton leak at all O2 levels. Hypoxia directly reduced FFA uptake and intracellular lipids uptake in myotubes, at least partially, due to the reduction in CD36 transporters. Metformin, but not GW501516, can increase FFA uptake and SCL27A4 expression under mild hypoxia. Described effects might contribute to elevated plasma FFA levels and metabolic derangements in OSA.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001590
003      
CZ-PrNML
005      
20201102101452.0
007      
ta
008      
190107s2018 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fendo.2018.00616 $2 doi
035    __
$a (PubMed)30386299
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Musutova, Martina $u Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia.
245    14
$a The Effect of Hypoxia and Metformin on Fatty Acid Uptake, Storage, and Oxidation in L6 Differentiated Myotubes / $c M. Musutova, M. Elkalaf, N. Klubickova, M. Koc, S. Povysil, J. Rambousek, B. Volckaert, F. Duska, MD. Trinh, M. Kalous, J. Trnka, K. Balusikova, J. Kovar, J. Polak,
520    9_
$a Metabolic impairments associated with obstructive sleep apnea syndrome (OSA) are linked to tissue hypoxia, however, the explanatory molecular and endocrine mechanisms remain unknown. Using gas-permeable cultureware, we studied the chronic effects of mild and severe hypoxia on free fatty acid (FFA) uptake, storage, and oxidation in L6 myotubes under 20, 4, or 1% O2. Additionally, the impact of metformin and the peroxisome proliferator-activated receptor (PPAR) β/δ agonist, called GW501516, were investigated. Exposure to mild and severe hypoxia reduced FFA uptake by 37 and 32%, respectively, while metformin treatment increased FFA uptake by 39% under mild hypoxia. GW501516 reduced FFA uptake under all conditions. Protein expressions of CD36 (cluster of differentiation 36) and SCL27A4 (solute carrier family 27 fatty acid transporter, member 4) were reduced by 17 and 23% under severe hypoxia. Gene expression of UCP2 (uncoupling protein 2) was reduced by severe hypoxia by 81%. Metformin increased CD36 protein levels by 28% under control conditions and SCL27A4 levels by 56% under mild hypoxia. Intracellular lipids were reduced by mild hypoxia by 18%, while in controls only, metformin administration further reduced intracellular lipids (20% O2) by 36%. Finally, palmitate oxidation was reduced by severe hypoxia, while metformin treatment reduced non-mitochondrial O2 consumption, palmitate oxidation, and proton leak at all O2 levels. Hypoxia directly reduced FFA uptake and intracellular lipids uptake in myotubes, at least partially, due to the reduction in CD36 transporters. Metformin, but not GW501516, can increase FFA uptake and SCL27A4 expression under mild hypoxia. Described effects might contribute to elevated plasma FFA levels and metabolic derangements in OSA.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Elkalaf, Moustafa $u Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Klubickova, Natalie $u Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Koc, Michal $u Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Povysil, Stanislav $u Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Rambousek, Jan $u Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Volckaert, Beatriz $u Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Duska, Frantisek $u Department of Anesthesiology and Intensive Care, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Trinh, Minh Duc $u Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Kalous, Martin $u Department of Cell Biology, Faculty of Science, Charles University, Prague, Czechia.
700    1_
$a Trnka, Jan $u Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Balusikova, Kamila $u Division of Cell and Molecular Biology, Third Faculty of Medicine, Department of Biochemistry, Cell and Molecular Biology & Center for Research of Diabetes, Metabolism and Nutrition, Charles University, Prague, Czechia.
700    1_
$a Kovar, Jan $u Division of Cell and Molecular Biology, Third Faculty of Medicine, Department of Biochemistry, Cell and Molecular Biology & Center for Research of Diabetes, Metabolism and Nutrition, Charles University, Prague, Czechia.
700    1_
$a Polak, Jan $u Department for the Study of Obesity and Diabetes, Third Faculty of Medicine, Charles University, Prague, Czechia.
773    0_
$w MED00174543 $t Frontiers in endocrinology $x 1664-2392 $g Roč. 9, č. - (2018), s. 616
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30386299 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20201102101453 $b ABA008
999    __
$a ind $b bmc $g 1365402 $s 1039713
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 9 $c - $d 616 $e 20181017 $i 1664-2392 $m Frontiers in endocrinology $n Front. endocrinol. $x MED00174543
GRA    __
$a NV15-30155A $p MZ0
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Možnosti archivace